TLT.V - Theralase Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.3700
-0.0150 (-3.90%)
As of 1:17PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3850
Open0.3850
Bid0.3650 x 0
Ask0.3700 x 0
Day's Range0.3650 - 0.3950
52 Week Range0.2700 - 0.6000
Volume428,374
Avg. Volume265,260
Market Cap53.329M
Beta (3Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-0.0260
Earnings DateAug 28, 2019 - Sep 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.38
  • ACCESSWIRE6 days ago

    Theralase Receives Notice of Acceptance for Multiwavelength Photo Dynamic Therapy from Russian Patent Office

    TORONTO, ON / ACCESSWIRE / July 16, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to announce that the Russian Patent Office has issued a Notice of Acceptance for a Multiwavelength Photo Dynamic Therapy (“PDT”) patent application. The patent application entitled, “Apparatus and Method for Multiwavelength Photo Dynamic Therapy” will issue into a patent later this year and provides additional international patent protection for the Company in the application of Theralase’s PDT technology for cancer.

  • ACCESSWIRE24 days ago

    Theralase Releases 2019 Annual General Meeting Video Presentations

    TORONTO, ON / ACCESSWIRE / June 28, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TLT:TSXV ) ( TLTFF:OTCQB ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE25 days ago

    Regulatory Updates from Health Canada and US FDA

    TORONTO, ON / ACCESSWIRE / June 27, 2019 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE26 days ago

    Health Canada Approves Amended Clinical Trial Application

    TORONTO, ON / ACCESSWIRE / June 26, 2019 / Theralase ® Technologies Inc. (" Theralase " or " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE27 days ago

    Theralase Brain Cancer Pre-Clinical Research Accepted for Publication

    TORONTO, ON / ACCESSWIRE / June 25, 2019 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that a scientific paper pertaining to the Company's Rutherrin® based PhotoDynamic Therapy ("PDT") has been peer reviewed and selected for publication in Neuro-Oncology Advances ("NOA"). Publication in NOA of Theralase's latest pre-clinical research of Rutherrin® PDT treatment targeting GlioBlastoma Multiforme ("GBM"), assisted through a collaboration with researchers at University Health Network's ("UHN") Princess Margaret Cancer Centre, allows many specialists in the field of neuro-oncology the opportunity to learn about Theralase's advances in this field.

  • Does Theralase Technologies Inc. (CVE:TLT) Have A Volatile Share Price?
    Simply Wall St.last month

    Does Theralase Technologies Inc. (CVE:TLT) Have A Volatile Share Price?

    Anyone researching Theralase Technologies Inc. (CVE:TLT) might want to consider the historical volatility of the share...

  • ACCESSWIRElast month

    Theralase Releases Amended and Restated 1Q2019 Financial Statements

    TORONTO, ON / ACCESSWIRE / June 18, 2019 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers filed its amended and restated condensed interim consolidated financial statements and Management Discussion and Analysis ("MD&A") as at and for the three-months ended March 31, 2019. Management of the Company has determined that the property lease for the Company's premises and office equipment was not properly recorded under International Financial Reporting Standards ("IFRS") 16 Leases, which came into effect on January 1, 2019 and provides guidance on how to recognize, measure, present and disclose leases.

  • ACCESSWIRElast month

    Voltaic Minerals Corp. Receives Conditional TSXV Acceptance for Binding Letter of Intent with 1146915 B.C. Ltd.

    VANCOUVER, BC / ACCESSWIRE / June 14, 2019 / Voltaic Minerals Corp. (TSX.V:VLT) (the "Corporation" or "Voltaic") is pleased to announce that it has received TSX Venture Exchange conditional acceptance for the binding Letter of Intent ("LOI") dated April 17, 2019 with 1146915 B.C. Ltd. ("PrivCo"), as first announced on April 22, 2019. Pursuant to the terms of the LOI, Voltaic and PrivCo will enter into a definitive Share Exchange Agreement (the "Definitive Agreement") whereby all outstanding securities of PrivCo will be exchanged for securities of Voltaic (the "Transaction"). The Transaction is an arm's length acquisition.

  • ACCESSWIRE2 months ago

    Theralase Releases 1Q 2019 Financial Statements

    TORONTO, ON / ACCESSWIRE / May 30, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers released its 1Q2019 financial statements. Total revenue for the three-month period ended March 31, 2019, decreased to $121,179 from $441,193 for the same period in 2018, a 73% decrease. In the US, revenue decreased 94% to $5,075 from $90,354 and international revenue decreased 100% from $53,778 to $Nil during the three-month period ended March 31, 2019.

  • ACCESSWIRE2 months ago

    Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office

    TORONTO, ON / ACESSWIRE / May 20, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE2 months ago

    Theralase’s 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

    TORONTO, ON / ACCESSWIRE / May 13, 2019 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE2 months ago

    Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy

    TORONTO, ON / ACCESSWIRE / May 7, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the Chinese Patent Office has Issued a Notice of Acceptance for a patent application concerning Multiwavelength PhotoDynamic Therapy ("PDT") to the Company. The patent entitled, "Apparatus and Method for Multiwavelength PhotoDynamic Therapy" validates the proprietary position of the Company and opens opportunities for the application of Theralase's PDT technology in an international market.

  • ACCESSWIRE3 months ago

    Theralase's Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association

    TORONTO, ON / ACCESSWIRE / May 6, 2019 / Theralase ® Technologies Inc. ('' Theralase '' or the '' Company '') ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated to the research ...

  • ACCESSWIRE3 months ago

    Theralase Commences Phase II NMIBC Clinical Study

    TORONTO, ON / ACCESSWIRE / April 25, 2019 / Theralase ® Technologies Inc. (" Theralase " or the " Company ") ( TLT:TSXV ) ( TLTFF:OTCQB ), a clinical stage pharmaceutical company dedicated ...

  • ACCESSWIRE3 months ago

    Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress

    Nine Scientific Papers Detailing the Latest Scientific Research of Theralase ® 's Anti-Cancer Technology ("ACT") Platform have been Peer Reviewed and will be Presented at the International Photodynamic ...

  • Is Theralase Technologies's (CVE:TLT) 132% Share Price Increase Well Justified?
    Simply Wall St.3 months ago

    Is Theralase Technologies's (CVE:TLT) 132% Share Price Increase Well Justified?

    When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right stock, you can make a lot more than 100%. For example, the Theralase Technologies Inc. (CVE:TLT) share pric...

  • ACCESSWIRE3 months ago

    Theralase(R) Releases 2018 Year End Audited Financial Statements

    TORONTO, ON / ACCESSWIRE / April 17, 2019 /Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers released the audited financial statements for the year ended December 31, 2018. In the US, revenue increased 16% to $304,785 from $261,833 and international revenue increased 62% to $223,975 from $138,665. The decrease in total revenue in 2018 is primarily due to the restructuring of the sales and marketing departments resulting in the termination of certain sales and marketing personnel and decreased spending in advertising.

  • ACCESSWIRE4 months ago

    Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment

    Results of Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study Demonstrate a 66% Complete Response ("CR") at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post Treatment ...

  • ACCESSWIRE4 months ago

    Theralase’s Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress

    TORONTO, ON / ACCESSWIRE / MARCH 26, 2019 /Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association ("IPA") World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019. IPA has been bringing together researchers and clinicians in all fields of PhotoDynamic Therapy ("PDT") and PhotoDiagnosis ("PD") since 1986.

  • ACCESSWIRE5 months ago

    Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds

    TORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has been granted allowance for a United States patent to issue later this year for destroying cancer cells with X-ray activated PDCs. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® and the lead inventor of the technology stated that, "In 2019, the Company plans to commence a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study, which if successful may lead to commercialization of this technology in Canada, the United States and the European Union.

  • ACCESSWIRE5 months ago

    Theralase Named to 2019 TSX Venture 50(TM)

    TORONTO, ON / ACCESSWIRE / February 28, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated photo dynamic compounds and their associated drug formulations intended to safely and effectively destroy various cancers has been named third place on the 2019 TSX Venture 50TM in the Clean Technology & Life Sciences sector amongst all TSX Venture Exchange listed companies. The ranking is comprised of ten companies from each of five industry sectors, selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount.

  • ACCESSWIRE5 months ago

    Theralase Announces Appointment of New Chief Executive Officers

    TORONTO, ON / ACCESSWIRE / February 25, 2019 / Theralase Technologies Inc. (" Theralase ® " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company ...

  • ACCESSWIRE6 months ago

    Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / January 31, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 360 day clinical and cystoscopy assessment. The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE6 months ago

    Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment

    TORONTO, ON / ACCESSWIRE / January 30, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study"), has demonstrated no tumour recurrence or presence of disease at the 270 day clinical and cystoscopy assessment. The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

  • ACCESSWIRE7 months ago

    Health Canada Grants ITA Approval to Commence Phase II Clinical Study

    TORONTO, ON / ACCESSWIRE / December 10, 2018 / Theralase Technologies Inc.(" Theralase® " or the " Company ") ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company ...